AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3891362
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C) 150 mg/m2 p.o. for 7 days q 4 weeks
Trial: 3891362
Drug: CAF (Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (Cyclophosphamide 400 mg/m2 i.v., doxorubicin 30 mg/m2, 5-fluorouracil 400 mg/m2 i.v., days 1 and 8 q 4 weeks)
Trial: 31584944
Drug: Wirelessly observed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wirelessly observed therapy (WOT)
Trial: 20551194
Drug: RCTs that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCTs that mentioned adverse drug reactions (ADRs)
Trial: 20551194
Drug: RCTs that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCTs that tabulated adverse drug reactions
Trial: 9566100
Drug: H15 (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H15 (3600 mg daily)
Trial: 7827399
Drug: Calcitriol 0.25
RxNorm normalized name: CALCITRIOL 0.25MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.25 microgram twice daily
Trial: 7827399
Drug: Calcitriol 0.5
RxNorm normalized name: CALCITRIOL 0.5MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day
Trial: 7827399
Drug: Elemental calcium
RxNorm normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental calcium 1000 mg/day
Trial: 3137320
Drug: Low-volume enteral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume enteral feeds (12 ml/kg/day) in addition to parenteral alimentation for 10 days starting on day 8 of life
Trial: 3137320
Drug: Parenteral alimentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral alimentation alone until day 18 of life
Trial: 18307077
Drug: Advance provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advance provision of emergency contraceptive pills (ECP), condoms, and an information leaflet
Trial: 17139825
Drug: Surfactant inhalations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant inhalations (700 mg cumulative dose over 8 weeks) during chemotherapy
Trial: 20141732
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (control group)
Trial: 12540551
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular vaccine
Trial: 12540551
Drug: Intranasal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunization with CRM197 without chitosan
Trial: 12540551
Drug: Unilateral intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral intranasal immunization
Trial: 8731520
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg THA (tacrine)
Trial: 8731520
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg THA (tacrine)
Trial: 29706227
Drug: DMPA‐SC self‐injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA‐SC self‐injection
Trial: 28514347
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment using ABO anthropometric system with indirect bonding
Trial: 28514347
Drug: Conventional orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional orthodontic treatment protocol
Trial: 23621161
Drug: high-dose statins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose statins
Trial: 20889053
Drug: Light-force chincup
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-force chincup (125-250 g)
Trial: 15128463
Drug: Decision aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aid for antithrombotic therapy
Trial: 11740232
Drug: IGF-1 treatment
RxNorm normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IGF-1 treatment
Trial: 3321873
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amniotomy and oxytocin
Trial: 2461906
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (HES) solution
Trial: 10566563
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg once daily for 10 days)
Trial: 14750614
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (250 mg twice daily for 10 days)
Trial: 1879394
Drug: d-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (30 mg)
Trial: 8912230
Drug: paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paroxetine (20 mg)
Trial: 3782648
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sublingual nifedipine
Trial: 1841020
Drug: Maintenance nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance nifedipine therapy
Trial: 6356628
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pirlindol
Trial: 6356628
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pirlindol
Trial: 6356628
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg pirlindol
Trial: 6356628
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg imipramine
Trial: 6356628
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tranylcypromine
Trial: 6337608
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nomifensine
Trial: 31050161
Drug: liraglutide-metformin
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide-metformin
Trial: 31050161
Drug: placebo-metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-metformin
Trial: 23538170
Drug: MABA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABA 400 μg once daily
Trial: 23538170
Drug: MABA 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABA 1200 μg once daily
Trial: 23538170
Drug: TIO +
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO + SAL (tiotropium 18 μg once daily plus salmeterol 50 μg twice daily)
Trial: 19551272
Drug: 2 alternate
RxNorm normalized name: ALTERNARIA ALTERNATA
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 alternate daily preprandial measurements
Trial: 19551272
Drug: 2 alternate
RxNorm normalized name: ALTERNARIA ALTERNATA
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 alternate daily pre‐ and postprandial measurements
Trial: 9094151
Drug: Loxiglumide (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (2.4 g/day)
Trial: 8249952
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (0.3 to 0.4 mg/kg)
Trial: 30054920
Drug: Liraglutide 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.9 mg/d
Trial: 30054920
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg/d
Trial: 25223724
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg twice daily for 52 weeks (group A)
Trial: 25223724
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg twice daily for 4 weeks and then 150 mg once daily (group B)
Trial: 20200257
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers)
Trial: 20200257
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of 80% CLA
Trial: 18519483
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 32 mg of docosahexaenoic acid and 31 mg of arachidonic acid per 100 mL of human milk
Trial: 11206237
Drug: Montelukast, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 10 mg
Trial: 18426147
Drug: Loratadine, 10
RxNorm normalized name: Loratadine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine, 10 mg
Trial: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 20% of control
Trial: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 40% of control (Group II)
Trial: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 60% of control (Group III)
Trial: 1758241
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 80% of control (Group IV)
Trial: 31872906
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (atorvastatin)
Trial: 31872906
Drug: Conventional statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional statin therapy
Trial: 27804174
Drug: Once-daily treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily treatment for asthma and COPD
Trial: 20726255
Drug: Control vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccines
Trial: 17931064
Drug: Relaxation response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation response (RR) tapes and soft music during acupuncture treatment; RR tapes listened to at home daily
Trial: 17931064
Drug: Soft music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft music during acupuncture treatment (control group)
Trial: 17931064
Drug: Relaxation response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation response (RR) tapes and soft music during acupuncture treatment
Trial: 16087945
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U once weekly for 12 months
Trial: 12390569
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered amoxicillin at 500 mg, 3 times daily for 14 days
Trial: 12390569
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered metronidazole at 250 mg, 3 times daily for 14 days
Trial: 12390569
Drug: SRP only
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP only or SRP followed by 14 days of orally administered doxycycline at 4 micro g/mL
Trial: 2649130
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with triiodothyronine)
Trial: 2649130
Drug: Sequential single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential single agent therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with vincristine)
Trial: 2649130
Drug: Sequential single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential single agent therapy
Trial: 7391628
Drug: A-Group: 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-Group: 900 mg of calcium, 50 mg of sodium fluoride, 50,000 units of vitamin D twice weekly
Trial: 7391628
Drug: B-Group: 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-Group: 900 mg of calcium, 50 mg of sodium fluoride
Trial: 7391628
Drug: C-Group: 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-Group: 50 mg of sodium fluoride
Trial: 7391628
Drug: D-Group: 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Group: 900 mg of calcium, 50 mg of sodium fluoride, 2 mg of estriol
Trial: 7391628
Drug: E-Group: 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-Group: 2 mg of estriol
Trial: 7391628
Drug: F-Group: 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-Group: 900 mg of calcium
Trial: 7391628
Drug: G-Group: 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Group: 900 mg of calcium, 2 mg of estriol
Trial: 26721134
Drug: Acupuncture-moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-moxibustion treatment (14 sessions, based on Zusanli, Yinlingquan, Zhongwan, Danzhong, Neiguan, Taichong, Ganshu, Geshu, Danshu)
Trial: 26721134
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Chinese herbs, one dose a day for 4 weeks)
Trial: 22405557
Drug: One-dose-adjuvanted primary
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose-adjuvanted primary administration followed by a single-adjuvanted booster dose containing a heterologous vaccine strain
Trial: 22405557
Drug: Increasing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the interval between the first and second dose (from 21 days to 12 months)
Trial: 22405557
Drug: HI antibody
RxNorm normalized name: Salmonella Typhi antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HI antibody response against the two strains
Trial: 22405557
Drug: Neutralizing antibody
RxNorm normalized name: Neutralizing antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibody responses and CMI
Trial: 22405557
Drug: Overall vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall vaccine
Trial: 21236421
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro maturation treatment
Trial: 9352699
Drug: Alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 2.5 mg three times daily
Trial: 8835055
Drug: Elemental zinc
RxNorm normalized name: Zinc, 220 mg (as elemental zinc 50 mg) oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental zinc supplementation in daily dosages of 25‐100 mg po
Trial: 1745854
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 0.2 mg
Trial: 1745854
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 1.0 mg
Trial: 6142748
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol 4 mg
Trial: 1745854
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol 8 mg
Trial: 7049385
Drug: Standard-dose CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CMF
Trial: 7049385
Drug: Low-dose CMF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CMF
Trial: 7049385
Drug: Overall CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall CMF (both doses)
Trial: 27100859
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the National Cancer Institute publication, 'Facing Forward: Life after Cancer Treatment.'
Trial: 25331236
Drug: 1-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Trial: 25331236
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Trial: 20685495
Drug: OLM/AZL 20/16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/AZL 20/16 mg
Trial: 20685495
Drug: OLM/AZL 10/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/AZL 10/8 mg
Trial: 18164463
Drug: Nonsurgical therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical therapies
Trial: 12094185
Drug: High diuretic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High diuretic doses
Trial: 12094185
Drug: Low angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low angiotensin-converting enzyme inhibitor dose
Trial: 10333344
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (12-15 g NaCl/day)
Trial: 10333344
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (1-3 g NaCl/day)
Trial: 8618187
Drug: Two-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose schedule at 1 and 3 months
Trial: 8618187
Drug: Two-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose schedule at 2 and 4 months
Trial: 8618187
Drug: Two-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose schedule at 2 and 6 months
Trial: 8618187
Drug: Two-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose schedule at 4 and 6 months
Trial: 8618187
Drug: Three-dose schedule
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose schedule at 2, 4, and 6 months
Trial: 1941708
Drug: Self-administered DIS
RxNorm normalized name: di-isopropylammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered DIS (S-DISSI)
Trial: 1941708
Drug: Interviewer-administered DIS
RxNorm normalized name: di-isopropylammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered DIS (I-DISSI)
Trial: 1941708
Drug: Traditional interviewer-administered
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional interviewer-administered DIS (T-DIS)
Trial: 26313245
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus
Trial: 29629619
Drug: Ezetimibe (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (oral formulations)
Trial: 28623823
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200mg twice daily
Trial: 25855851
Drug: Topical platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical platelet derived growth factor (Regranex)
Trial: 25633134
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day
Trial: 10684841
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.5%)
Trial: 8956632
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost (0.005%)
Trial: 1578922
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX (Regimen A)
Trial: 1578922
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus asparaginase (Regimen B)
Trial: 1578922
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given early (Regimen C)